An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report from IQVIA — a company that tracks prescription data — looked at how often two weight-loss drugs, semaglutide and tirzepatide, were prescribed in the third quarter of 2024. The headline is about prescription trends and what doctors and patients are using these medicines for. The story is mostly about numbers and patterns in who is getting these drugs, not a new clinical trial or a sudden safety recall. Semaglutide and tirzepatide are drugs that help people lose weight. Semaglutide is the active ingredient in medicines like Ozempic and Wegovy; it acts like a hormone your gut makes after you eat that tells the brain you’re full and slows how fast your stomach empties. Tirzepatide is a newer medicine that mimics two gut hormones at once, which seems to reduce appetite and improve how the body handles sugar. Both are given by injection and were originally developed to treat diabetes; they’ve become widely prescribed for weight management as well. The IQVIA report looks at prescription volumes and likely reasons for use across the U.S. in that three-month window. That means it’s tracking real-world prescribing behavior — how many people are getting these drugs, whether prescriptions are for diabetes or for weight loss, and possibly which doctors are writing them. This is not a study testing how well they work; it’s a snapshot of how widely they’re being used. So it can show big shifts in popularity or access but doesn’t on its own prove new benefits or harms. Why this matters is practical. If prescriptions are rising, that means more people are getting access to powerful medicines that can lead to significant weight loss and improvements in conditions like type 2 diabetes. It also affects drug supply, insurance coverage, and how easy it is for patients to get appointments or fill prescriptions. People considering these drugs — or doctors deciding whether to prescribe them — will want to know how commonly they’re being used and whether access is changing. There are important caveats. These drugs can cause side effects like nausea, diarrhea, and stomach discomfort, and they aren’t right for everyone; people with certain medical histories need close evaluation. The IQVIA data describe prescribing patterns, not long-term safety in everyone who takes the drugs. Insurance coverage varies, and off-label use (using a drug for a purpose it wasn’t officially approved for) can occur. Lastly, trends in prescriptions don’t guarantee outcomes for any individual patient. Bottom line: The IQVIA snapshot shows how semaglutide and tirzepatide are being prescribed in mid-2024, which is useful for understanding access and trends, but it doesn’t replace medical advice or clinical trial evidence about benefits and risks.
Source: EMY